Literature DB >> 17131366

Expression of RBM5-related factors in primary breast tissue.

Nina D Rintala-Maki1, Carolyn A Goard, Colleen E Langdon, Vanessa E Wall, Kathryn E A Traulsen, Cory D Morin, Michel Bonin, Leslie C Sutherland.   

Abstract

The aim of this study was to examine the expression of the RBM5 tumor suppressor, in relation to RBM6 and RBM10, to obtain a better understanding of the potential role played by these RBM5-related factors in the regulation of RBM5 tumor-suppressor activity. Paired non-tumor and tumor samples were obtained from 73 breast cancer patients. RNA and protein expression were examined by semi-quantitative reverse transcription-polymerase chain reaction and immunoblot, respectively. Data were analyzed using various statistical methods to test for correlations amongst the RBM5-related factors, and between the factors and various pathological parameters. Most notably, RBM5, RBM10v1, and HER2 protein expression levels were elevated in tumor tissue (P < 0.0001). RBM5 and RBM10v1 protein expression were significantly positively correlated (P < 0.001), as were RBM5 and HER2 protein expression (P < 0.01), in both non-tumor and tumor tissue, whereas RBM10v1 and HER2 protein expression were only marginally correlated, in non-tumor tissue (P < 0.05). Interestingly, RBM5 and RBM10v1 protein expression were both deregulated in relation to RNA expression in tumor tissue. RBM10v2 and RBM6 RNA were highly significantly positively correlated in relation to various factors relating to poor prognosis (P < 0.0001). To our knowledge, this study is the first to examine RBM5 expression at both the RNA and protein level in primary breast tumor tissue, and the first to examine expression of all RBM5-related factors in a comprehensive manner. The results provide a graphic illustration that RBM5-related factors are significantly differentially expressed in breast cancer, and suggest complex inter-related regulatory networks involving alternative splicing, oncogenic expression, and tissue-specific function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17131366     DOI: 10.1002/jcb.21134

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  19 in total

1.  Targeting zinc finger domains with small molecules: solution structure and binding studies of the RanBP2-type zinc finger of RBM5.

Authors:  Biancamaria Farina; Roberto Fattorusso; Maurizio Pellecchia
Journal:  Chembiochem       Date:  2011-12-16       Impact factor: 3.164

Review 2.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

3.  Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins.

Authors:  Akihide Yoshimi; Omar Abdel-Wahab
Journal:  Clin Cancer Res       Date:  2016-11-10       Impact factor: 12.531

4.  Up-regulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5.

Authors:  Kazuo Fushimi; Payal Ray; Amar Kar; Lei Wang; Leslie C Sutherland; Jane Y Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-07       Impact factor: 11.205

5.  Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma.

Authors:  Jian Hong; Yunfei Yuan; Jianping Wang; Yadi Liao; Ruhai Zou; Chuanlong Zhu; Binkui Li; Yi Liang; Pinzhu Huang; Zongwei Wang; Wenyu Lin; Yixin Zeng; Jia Le Dai; Raymond T Chung
Journal:  Cancer Res       Date:  2014-01-29       Impact factor: 12.701

Review 6.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

7.  Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.

Authors:  Hong Liang; Jie Zhang; Chen Shao; Lijing Zhao; Wei Xu; Leslie C Sutherland; Ke Wang
Journal:  J Exp Clin Cancer Res       Date:  2012-04-26

Review 8.  RNA splicing factors as oncoproteins and tumour suppressors.

Authors:  Heidi Dvinge; Eunhee Kim; Omar Abdel-Wahab; Robert K Bradley
Journal:  Nat Rev Cancer       Date:  2016-06-10       Impact factor: 60.716

9.  Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features.

Authors:  Jie Peng; Ali Kord Valeshabad; Qingfu Li; Yuan Wang
Journal:  Oncol Lett       Date:  2012-12-17       Impact factor: 2.967

10.  RBM6-RBM5 transcription-induced chimeras are differentially expressed in tumours.

Authors:  Ke Wang; Gino Ubriaco; Leslie C Sutherland
Journal:  BMC Genomics       Date:  2007-10-01       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.